Clinical trial

A Phase II Prospective Randomized Trial of Donor T-memory Cells (CD45RA Depleted) Infusion for Prevention of Infections After Allogeneic TcRαβ/CD19-depleted Hematopoietic Stem Cell Transplantation

Name
CD45RAndom_2016_1
Description
The purpose of this prospective randomized study is to determine whether infusions of T-memory cells prevent infections in children with leukemia after allogeneic alpha, beta T-cell receptor (TcRab)/CD19-depleted hematopoietic stem cell transplantation (HSCT).
Trial arms
Trial start
2016-10-01
Estimated PCD
2019-08-21
Trial end
2020-08-21
Status
Completed
Phase
Early phase I
Treatment
CD45RA-depleted peripheral blood mononuclear cells
Infusion of escalating doses of CD45RA-depleted donor-derived allogeneic peripheral blood mononuclear cells
Arms:
CD45RA+
Size
150
Primary endpoint
cumulative incidence of the probability of CMV-reactivation after HSCT
120 days after HSCT
cumulative incidence of acute GVHD grade II-IV.
150 days after HSCT
Eligibility criteria
Inclusion Criteria: * Patients who are considered candidates for allogeneic hematopoietic stem cell transplantation and have one of the following diagnoses: * Acute lymphocytic leukemia (ALL) * Acute myeloid leukemia * Acute biphenotypic leukemia * Acute bilinear leukemia * Lymphoma * Myelodysplastic syndrome * Chronic myeloid leukemia * Transplant processing: TCR ab/CD19-depletion * Donors: * HLA-match unrelated volunteers * Partly and haploidentical relative Exclusion Criteria: * ALL patients not in remission * Patients with uncontrolled infections * Clearance of creatinine \< 70 ml/min * Cardiac ejection fraction \< 40% * Patients who can perform pulmonary function tests will be excluded if they have a diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin) of \< 50% predicted; patients who are unable to perform pulmonary function tests will be excluded if the oxygen (O2) saturation is \< 92% on room air * Patients who have liver function test (LFTs) (including total bilirubin, aspartate aminotransferase \[AST\] and alanine aminotransferase \[ALT\]) \>= twice the upper limit of normal * Mental disease of both patient, patient's tutor (if patient is under age 18) and donor, that hinder understanding of main point of the study and keeping treatment plan, hygiene and sanitation
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2', 'PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 150, 'type': 'ACTUAL'}}
Updated at
2023-03-16

1 organization

1 product

6 indications

Indication
Leukemia
Indication
lymphoma
Indication
GvHD